Eric Venker compensation by year
Immunovant Summary Compensation Table · the one fiscal year held| Component | FY2026 |
|---|---|
| Salary | $636,618 |
| Bonus | $503,345 |
| Stock awards | $0 |
| Option awards | $19,010,639 |
| Non-equity incentive | $0 |
| Pension and deferred compensation | $0 |
| All other | $8,165 |
| Total | $20,158,767 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Immunovant, Inc. DEF 14A filed July 22, 2026, accession 0001764013-26-000092, and prior-year filings.
How this page was built: the Immunovant, Inc. filed document, accession 0001764013-26-000092. Every figure is read from that document and cited to the page and table it appears in. Filed July 22, 2026.
Equity holdings
unvested awards at FY2026 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| Option | 1,475,000 | — | $14.46 |
| Option | 1,489,900 | — | $16.76 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Immunovant, Inc.'s FY2026 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
4 Form 4 lines since the FY2026 proxy (filed July 22, 2026)current to 2026-11-06 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-10-02 | Sale | — | 3,506 | $34.11 | 257,075 |
| 2026-10-01 | Exercise or conversion derivative | — | 92,187 | $0.00 | 921,875 |
| 2026-10-01 | Exercise or conversion | — | 92,187 | $14.46 | 346,467 |
| 2026-10-01 | Disposition to the issuer | — | 85,886 | $33.65 | 260,581 |
The 4 most recent of 4 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Immunovant’s named executive officers, FY2026
as the company reported each| Named executive officer | Role | FY2026 total |
|---|---|---|
| Eric Venker · this page | Chief Executive Officer | $20,158,767 |
| Peter Salzmann | Former Chief Executive Officer | $15,334,600 |
| Tiago Girão | Chief Financial Officer | $7,616,437 |
| Michael Geffner | Former Chief Medical Officer | $5,254,089 |
| Eva Renee Barnett | Former Chief Financial Officer | $3,227,452 |
| Melanie Gloria | Chief Operating Officer | $3,067,112 |
| Jay Stout | Chief Technology Officer | $3,065,721 |
| Christopher Van Tuyl | Chief Legal Officer and Corporate Secretary | $2,295,777 |
Board service
Immunovant board · FY2024| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2024 | $55,000 | $0 | $0 | — | $55,000 |
Each year as the company reported it in Immunovant's director compensation table. Totals are the company's own disclosed totals.
How this board is paid
Company policy: Immunovant pays directors a $50,000 cash retainer and $788,000 in 50% Options / 50% RSUs. As stated in Immunovant's FY2024 proxy.
The full Immunovant compensation record
free company briefThis page is one person within Immunovant's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Immunovant proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Immunovant's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Immunovant's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.